Results presented by Avidity of interim data from its Phase 1/2 clinical trial in FSHD were all the buzz at this year’s International Research Congress and FSHD Connect conference…. Read More »
Meet del-brax, Avidity’s FSHD therapeutic candidate
Avidity shares interim data from its FORTITUDE trial
“Unprecedented” and “consistent” reductions in DUX4 activity along with improvements in strength and function by June Kinoshita, FSHD Society Avidity Biosciences, Inc., a San Diego-based biopharmaceutical company, announced this Wednesday,… Read More »
Fulcrum Therapeutics and Sanofi to collaborate
Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights Read the full news release here CAMBRIDGE, Mass., May 13, 2024… Read More »
Calgary 360 slides
Here are the slides from the Calgary FSHD 360 meeting on March 16, 2024. Welcome! What is a 360? What is the CTRN? Beth Johnston, FSHD Society, and Neil Camarta,… Read More »
Is MRI the “holy grail” for FSHD clinical trials?
The MOVE+ study aims to find out. Participants needed! by June Kinoshita, FSHD Society Imagine that you are in an FSHD clinical trial a few years in the future. On… Read More »